

Joseph S Doyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1052029/publications.pdf>

Version: 2024-02-01

119
papers

4,323
citations

147566

31
h-index

118652

62
g-index

120
all docs

120
docs citations

120
times ranked

5930
citing authors

#	ARTICLE	IF	CITATIONS
1	The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009–2019. <i>Clinical Infectious Diseases</i> , 2022, 74, 1804-1811.	2.9	11
2	Screening for risky drinkers among hospitalised inpatients using the <scp>AUDIT</scp>: A feasibility, point prevalence and data linkage study. <i>Drug and Alcohol Review</i> , 2022, 41, 293-302.	1.1	0
3	High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH Study. <i>Hepatology Communications</i> , 2022, 6, 496-512.	2.0	10
4	A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia. <i>Liver International</i> , 2022, 42, 522-531.	1.9	4
5	Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study). <i>BMJ Open</i> , 2022, 12, e057618.	0.8	1
6	Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia. <i>BMC Public Health</i> , 2022, 22, 536.	1.2	1
7	The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 375-384.	1.0	11
8	Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol. <i>BMJ Open</i> , 2022, 12, e056120.	0.8	0
9	Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020. <i>International Journal of Drug Policy</i> , 2022, 103, 103655.	1.6	8
10	“œlt”™s not just the hit itself” the social practice of injecting drug use among gay and bisexual men in Australia. <i>International Journal of Drug Policy</i> , 2022, 103, 103642.	1.6	7
11	Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019. <i>Epidemiology and Infection</i> , 2022, 150, e7.	1.0	1
12	Hospitalisation with injection-related infections: Validation of diagnostic codes to monitor admission trends at a tertiary care hospital in Melbourne, Australia. <i>Drug and Alcohol Review</i> , 2022, 41, 1053-1061.	1.1	2
13	Hepatitis B and pregnancy: understanding the experiences of care among pregnant women and recent mothers in metropolitan Melbourne. <i>BMC Public Health</i> , 2022, 22, 817.	1.2	2
14	Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1512-1523.	1.9	5
15	Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020. <i>International Journal of Drug Policy</i> , 2022, 104, 103696.	1.6	2
16	Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e2164-e2172.	2.9	30
17	Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. <i>Clinical Infectious Diseases</i> , 2021, 73, e3288-e3295.	2.9	21
18	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	1.0	28

#	ARTICLE	IF	CITATIONS
19	Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study. <i>International Journal of Drug Policy</i> , 2021, 87, 102983.	1.6	8
20	The phases of hepatitis C elimination: achieving WHO elimination targets. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 6-8.	3.7	27
21	Letter to the Editor: Recommendations for Implementing Hepatitis C Virus Care in Homeless Shelters: The Stakeholder Perspective. <i>Hepatology Communications</i> , 2021, 5, 146-147.	2.0	1
22	Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care. <i>Journal of Viral Hepatitis</i> , 2021, 28, 771-778.	1.0	19
23	Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1068-1077.	1.0	6
24	Early antimicrobial stewardship team intervention on appropriateness of antimicrobial therapy in suspected sepsis: a randomized controlled trial. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab097.	0.9	5
25	A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1624-1634.	1.0	2
26	Brief Report: Low Incidence of Hepatitis C Among a Cohort of HIV-Negative Gay and Bisexual Men Using HIV Pre-exposure Prophylaxis (PrEP) in Melbourne, Australia, and the Contribution of Sexual Transmission. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1011-1015.	0.9	4
27	Letter in response: Psychiatrists can treat hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1765-1766.	1.0	0
28	œt's time! A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C. <i>International Journal of Drug Policy</i> , 2021, 97, 103280.	1.6	2
29	Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2020, 70, 1900-1906.	2.9	61
30	Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1502-1510.	2.9	46
31	A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. <i>International Journal of Drug Policy</i> , 2020, 76, 102633.	1.6	17
32	Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure. <i>International Journal of Drug Policy</i> , 2020, 75, 102596.	1.6	6
33	Commentary on Barrã© et al. (2020): Identifying remaining barriers to hepatitis C treatment in the DAA era. <i>Addiction</i> , 2020, 115, 583-584.	1.7	0
34	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. <i>Nature Medicine</i> , 2020, 26, 1941-1949.	15.2	58
35	Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. <i>Aids</i> , 2020, 34, 1347-1358.	1.0	12
36	Clinical care of pregnant and postpartum women with COVIDã©19: Living recommendations from the National COVIDã©19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 840-851.	0.4	36

#	ARTICLE	IF	CITATIONS
37	Reaching methadone users attending community pharmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV). <i>BMJ Open</i> , 2020, 10, e036501.	0.8	10
38	Population patterns in Alcohol Use Disorders Identification Test (AUDIT) scores in the Australian population; 2007–2016. <i>Australian and New Zealand Journal of Public Health</i> , 2020, 44, 462-467.	0.8	18
39	Measuring hepatitis C virus elimination as a public health threat: Beyond global targets. <i>Journal of Viral Hepatitis</i> , 2020, 27, 770-773.	1.0	4
40	Australia needs to increase testing to achieve hepatitis C elimination. <i>Medical Journal of Australia</i> , 2020, 212, 365-370.	0.8	43
41	The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services. <i>PLoS ONE</i> , 2020, 15, e0235445.	1.1	12
42	Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection. <i>Scientific Reports</i> , 2020, 10, 1459.	1.6	7
43	The Elimination of Hepatitis C as a Public Health Threat. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036939.	2.9	4
44	Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0242101.	1.1	6
45	The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, e81-e89.	0.9	0
46	Title is missing!. , 2020, 15, e0242101.		0
47	Title is missing!. , 2020, 15, e0242101.		0
48	Title is missing!. , 2020, 15, e0242101.		0
49	Title is missing!. , 2020, 15, e0242101.		0
50	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 511-519.	1.0	2
51	Reducing alcohol-related harm in people recently treated for hepatitis C. <i>Australian Journal of Primary Health</i> , 2019, 25, 193.	0.4	0
52	Retreatment with elbasvir, grazoprevir, sofosbuvir±dabpravirin is effective for GT3 and GT1/4/6 HCV infection after relapse. <i>Liver International</i> , 2019, 39, 2285-2290.	1.9	5
53	Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department. <i>International Journal of Drug Policy</i> , 2019, 72, 84-90.	1.6	21
54	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. <i>Clinics in Liver Disease</i> , 2019, 23, 487-492.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 493-509.	1.0	4
56	Screening and Prophylaxis to Prevent Hepatitis B Reactivation. Clinics in Liver Disease, 2019, 23, 521-534.	1.0	2
57	Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. Journal of Hepatology, 2019, 70, 839-846.	1.8	80
58	Hepatitis C risk perceptions and attitudes towards reinfection among <sc>HIV</sc>-diagnosed gay and bisexual men in Melbourne, Australia. Journal of the International AIDS Society, 2019, 22, e25288.	1.2	9
59	Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study. International Journal of Drug Policy, 2019, 72, 91-98.	1.6	39
60	Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver International, 2019, 39, 2244-2260.	1.9	36
61	Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Medical Journal of Australia, 2019, 210, 462-468.	0.8	13
62	Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. International Journal of Drug Policy, 2019, 72, 195-198.	1.6	32
63	FRI-233-The impact of community-based rapid point-of-care testing on enhancing uptake of hepatitis C treatment for people who inject drugs in needle and syringe services. Journal of Hepatology, 2019, 70, e497.	1.8	2
64	Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs. Journal of Viral Hepatitis, 2019, 26, 919-922.	1.0	27
65	Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia. Alimentary Pharmacology and Therapeutics, 2019, 49, 1223-1229.	1.9	34
66	Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 40-48.	1.4	39
67	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	3.7	370
68	Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience. Journal of Viral Hepatitis, 2019, 26, 218-223.	1.0	11
69	Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2018, 67, 676-686.	2.9	326
70	Linkage and retention in <sc>HCV</sc> care for <sc>HIV</sc>-infected populations: early data from the <sc>DAA</sc> era. Journal of the International AIDS Society, 2018, 21, e25051.	1.2	40
71	Eliminating hepatitis C virus as a public health threat among <sc>HIV</sc>-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour. Journal of the International AIDS Society, 2018, 21, e25059.	1.2	21
72	Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. Journal of Infectious Diseases, 2018, 217, 1033-1043.	1.9	24

#	ARTICLE	IF	CITATIONS
73	Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment?. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 411-422.	2.0	4
74	Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1472-1480.	1.0	27
75	Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study. <i>BMC Infectious Diseases</i> , 2018, 18, 151.	1.3	7
76	Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access. <i>Journal of Virus Eradication</i> , 2018, 4, 108-114.	0.3	8
77	Injecting drug use in low and middle-income countries: Opportunities to improve care and prevent harm. <i>Journal of Viral Hepatitis</i> , 2017, 24, 714-724.	1.0	15
78	Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. <i>Gut</i> , 2017, 66, 1507-1515.	6.1	119
79	Pathways to the elimination of hepatitis C: prioritising access for all. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1023-1026.	1.3	12
80	Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. <i>International Journal of Drug Policy</i> , 2017, 47, 107-116.	1.6	114
81	New hepatitis C antiviral treatments eliminate the virus. <i>Lancet, The</i> , 2017, 390, 358-359.	6.3	5
82	A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy. <i>Australian Family Physician</i> , 2017, 46, 235-240.	0.5	10
83	Local transmission of hepatitis E virus in Australia: implications for clinicians and public health. <i>Medical Journal of Australia</i> , 2016, 204, 254-254.	0.8	0
84	A systematic review of community based hepatitis C treatment. <i>BMC Infectious Diseases</i> , 2016, 16, 202.	1.3	41
85	Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 872-882.	1.4	47
86	Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 1151-1154.	2.0	28
87	Field engagement further facilitates hepatitis B vaccination completion. <i>Journal of Clinical Virology</i> , 2016, 82, 64-65.	1.6	0
88	The impact of a multidisciplinary antimicrobial stewardship team on the timeliness of antimicrobial therapy in patients with positive blood cultures: a randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3276-3283.	1.3	30
89	Direct-acting antiviral treatment for HCV. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 1325-1326.	4.6	4
90	HIV and Sexual Risk Among Men Who Have Sex With Men and Women in Asia: A Systematic Review and Meta-Analysis. <i>AIDS and Behavior</i> , 2016, 20, 2243-2265.	1.4	44

#	ARTICLE	IF	CITATIONS
91	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS ONE, 2016, 11, e0150655.	1.1	15
92	Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. Journal of Viral Hepatitis, 2015, 22, 1020-1032.	1.0	10
93	The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service. PLoS ONE, 2015, 10, e0142770.	1.1	49
94	Global policy and access to new hepatitis C therapies for people who inject drugs. International Journal of Drug Policy, 2015, 26, 1064-1071.	1.6	14
95	Hepatitis C transmission and treatment as prevention – The role of the injecting network. International Journal of Drug Policy, 2015, 26, 958-962.	1.6	53
96	Cognitive Behavioral Therapy for Chronic Insomnia. Annals of Internal Medicine, 2015, 163, 191-204.	2.0	706
97	Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. European Journal of Epidemiology, 2015, 30, 115-129.	2.5	32
98	Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. International Journal of Epidemiology, 2014, 43, 235-248.	0.9	298
99	Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology, 2014, 59, 366-369.	3.6	78
100	Effects of HIV Antiretroviral Therapy on Sexual and Injecting Risk-Taking Behavior: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1483-1494.	2.9	33
101	Interferon-free hepatitis C treatment: one pill to fit all?. Lancet, The, 2014, 383, 491-492.	6.3	7
102	Latent Tuberculosis Screening Using Interferon-Gamma Release Assays in an Australian HIV-Infected Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 48-54.	0.9	16
103	Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 707-716.	1.4	24
104	Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2013, 57, S80-S89.	2.9	280
105	Current and emerging antiviral treatments for hepatitis C infection. British Journal of Clinical Pharmacology, 2013, 75, 931-943.	1.1	42
106	Beyond injecting drug use: investigation of a Victorian cluster of hepatitis C among HIV-infected men who have sex with men. Medical Journal of Australia, 2013, 198, 210-214.	0.8	19
107	Prescribing trends before and after implementation of an antimicrobial stewardship program. Medical Journal of Australia, 2013, 198, 262-266.	0.8	55
108	Non-cirrhotic portal hypertension in HIV mono-infected patients. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1512-1519.	1.4	10

#	ARTICLE	IF	CITATIONS
109	The role of viral and host genetics in natural history and treatment of chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 413-427.	1.0	24
110	Acute Hepatitis C Infection: New Approaches to Surveillance, Treatment and Prevention. <i>Current Hepatitis Reports</i> , 2012, 11, 221-230.	0.3	3
111	Two forms of immunological recovery and immune reconstitution inflammatory syndrome in one patient. <i>Medical Journal of Australia</i> , 2012, 197, 92-93.	0.8	0
112	Murray Valley encephalitis: a review of clinical features, diagnosis and treatment. <i>Medical Journal of Australia</i> , 2012, 196, 322-326.	0.8	73
113	Opportunistic serological surveillance for Murray Valley encephalitis virus in Victoria, February–May 2011. <i>Medical Journal of Australia</i> , 2012, 197, 150-150.	0.8	3
114	Mumps presenting as epididymo-orchitis among young travellers: under-recognition, missed diagnoses and transmission risks. <i>Medical Journal of Australia</i> , 2011, 194, 317-318.	0.8	2
115	Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. <i>Journal of Neurosurgery</i> , 2011, 114, 458-462.	0.9	43
116	Epidemiology of Infections Acquired in Intensive Care Units. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 115-138.	0.8	75
117	Cardiac Epithelioid Leiomyosarcoma and the Role of Cardiac Imaging in the Differentiation of Intracardiac Masses. <i>Clinical Cardiology</i> , 2010, 33, E6-9.	0.7	15
118	Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia. <i>Emerging Infectious Diseases</i> , 2010, 16, 1068-1075.	2.0	108
119	An international public health crisis: can global institutions respond effectively to HIV/AIDS?. <i>Australian Journal of International Affairs</i> , 2006, 60, 400-411.	0.8	6